These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17514806)

  • 1. Long-term Mitomycin C is better for bladder cancer.
    Gould P
    Lancet Oncol; 2007 May; 8(5):377. PubMed ID: 17514806
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
    Huland H; Otto U; Droese M; Klöppel G
    J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stage P-1 primary neoplasia of the bladder. Critical evaluation of results obtained with the use of adriamycin and mitomycin C in the prevention of recurrences].
    Liberti M; Tenaglia R; De Berardinis E; Gentile V
    Minerva Med; 1984 Feb; 75(8):391-4. PubMed ID: 6424059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatic recurrences in the management of superficial bladder tumors.
    Lockhart JL; Chaikin L; Bondhus MJ; Politano VA
    J Urol; 1983 Aug; 130(2):256-7. PubMed ID: 6410083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic use of mitomycin C in bladder cancer.
    Denis L
    Prog Clin Biol Res; 1984; 162B():113-22. PubMed ID: 6438638
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitomycin C in superficial bladder cancer: 24-month follow-up.
    Somerville JJ; Newling DW; Richards B; Robinson MR; Smith PH
    Br J Urol; 1985 Dec; 57(6):686-9. PubMed ID: 3936564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitomycin C therapy in superficial bladder cancer.
    Denis L; Keuppens F; Hendrickx G
    Prog Clin Biol Res; 1985; 185B():113-22. PubMed ID: 3929269
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy for bladder cancer.
    Whitmore WF
    J Urol; 1985 Dec; 134(6):1181-2. PubMed ID: 3932688
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma levels during intravesical instillation of mitomycin-C.
    Kurth KH; de Wall JG; van Oosterom AT; de Jong EA; Tjaden UR
    Prog Clin Biol Res; 1985; 185B():81-93. PubMed ID: 3929272
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic mitomycin C versus cisplatin: comparison of antitumor activity in primary murine bladder cancer.
    Hopkins SC; Matheny R; Soloway MS
    Urology; 1982 Aug; 20(2):157-9. PubMed ID: 6810530
    [No Abstract]   [Full Text] [Related]  

  • 12. [Local mitomycin-C therapy of infiltrating bladder cancer].
    Erdmann WD; Harzmann R; Flüchter SH; Bichler KH
    Fortschr Med; 1984 Aug; 102(29-30):767-71. PubMed ID: 6437950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1)].
    Allona Moncada A; García Vaquero S; Zuloaga Gómez A; Martínez Torres JL; López-Pardo R; Molina J; Camacho JE; Rodríguez Rubio F; Varo C
    Actas Urol Esp; 1988; 12(5):424-9. PubMed ID: 3146214
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.
    Niijima T; Koiso K; Akaza H
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S79-82. PubMed ID: 6416701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of carcinoma of the bladder by infusion of the anticancer agent (mitomycin C) via the internal iliac artery.
    Ogata J; Migita N; Nakamura T
    J Urol; 1973 Dec; 110(6):667-70. PubMed ID: 4757549
    [No Abstract]   [Full Text] [Related]  

  • 17. [Intravesical instillation for bladder tumors].
    Rivière A; Ploussard G; Desgranchamps F
    Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
    Wajsman Z; Dhafir RA; Pfeffer M; MacDonald S; Block A; Dragone N; Pontes JE
    J Urol; 1984 Jul; 132(1):30-3. PubMed ID: 6427484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.